We aimed to investigate the role of XRCC1 codon 194 (Arg>Trp), 280 (Arg>His), and 399 (Arg>Gln) polymorphisms in response to chemotherapy and the overall survival of gastric cancer patients. A total of 172 patients were recruited for our study between January 2010 and March 2012. Genotyping of the three XRCC1 codons was carried out by restriction fragment length polymorphism polymerase chain reaction.
Numerous studies have evaluated the association between Arg399Gln polymorphism of DNA repair gene XRCC1 and cervical carcinoma risk. However, the specific association is still controversial. To assess the relationship between XRCC1 Arg399Gln polymorphism and cervical carcinoma, we conducted a comprehensive meta-analysis of 10 case-control studies with 2051 cervical carcinoma cases and 2919 controls.
We investigated the association between the polymorphisms GSTP1 rs1695 and XRCC1 rs1799782 and rs25487 and the clinical outcome of patients with non-small cell lung cancer (NSCLC) receiving cisplatin-based chemotherapy. Genotyping of GSTP1 rs1695 and XRCC1 rs1799782, and rs25487 was conducted by polymerase chain reaction-restriction fragment length polymorphism analysis.